Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Global Exosome-Based Therapeutics Market Size, Share, Trends, and Forecast, 2026-2033 | Engineered Platforms and Scalable Manufacturing Fuel 18.66% CAGR to USD 220.20 MillionInvestment, strategic collaborations, scalable production and advanced cargo loading are accelerating exosome therapies across oncology, neurology and regenerative medicine.
- Luminous Mind, Inc.Luminous Mind, Inc. Announces U.S. Patent for Non-Hallucinogenic Psychedelic MushroomsLuminous Mind, Inc. seeks strategic partnerships with leading nutraceutical, supplement, pharmaceutical, and venture groups to bring breakthrough products to market, potentially opening a billion-dollar-plus opportunity. BOSTON, Oct. 6, 2026 -- Luminous Mind, Inc. (LMI), a...
- 60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA60 Degrees plans January 2027 results from its hospitalized babesiosis trial and will seek a pre-sNDA meeting with FDA.
- Alora Pharmaceuticals, LLCOnce-daily RELEXXII® (methylphenidate hydrochloride extended-release tablet) supports Attention Deficit Hyperactivity Disorder (ADHD) Awareness MonthOctober marks ADHD Awareness Month, shining a light on the need for timely diagnosis and personalized treatment. Vertical Pharmaceuticals is dedicated to supporting the ADHD community and the importance of precision dosing. Approximately 11.7%...
- API Innovation Center Launches the U.S.’ First Benchmark for Pharmaceutical Supply Chain FragilityMore than 550 million prescriptions were filled for medicines with High or Severe supply-chain fragility, according to APIIC’s new national benchmark
- BullFrog AI Announces Positive Progress in Drug Discovery Program for Top 5 Global Pharmaceutical in Major Depressive DisorderAchieves key commercial project milestones utilizing its proprietary artificial intelligence (“AI”) and machine learning platform to identify and prioritize therapeutic targets
- Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced participation in the upcoming AASLD Liver Meeting 2026. The Company will deliver three presentations, including an oral presentation, a Poster of Distinction presentation, and one poster presentation, highlighting new risk analyses on noninvasive prediction of variceal development from the NAVIGATE and GT-026 Phase 2b trials of belapectin for the treatment of MASH cirrhosis and portal hypertension. The meeting will be held November 5-9, 2026, in Denver, Colorado.
- /C O R R E C C I O N -- Piramal Pharma Solutions/Piramal Pharma Solutions ("PPS"), una organización líder mundial de desarrollo y fabricación por contrato (CDMO) y parte de Piramal Pharma Ltd....
- /C O R R E C T I O N -- Piramal Pharma Solutions/Dans le communiqué de presse « Piramal Pharma Solutions inaugure un nouveau laboratoire de microbiologie dans son site de fabrication de produits injectables stériles de Lexington, dans le Kentucky », publié le 6 octobre 2026 par Piramal Pharma Solutions via PR Newswire, la société nous...
- H. Lundbeck A/SLundbeck presents Phase Ib data for Lu AF28996 in advanced Parkinson's disease, as Phase II trial beginsResults from an 18-week, open-label Phase Ib trial of investigational Lu AF28996 in people with advanced Parkinson's disease are being presented at MDS 2026 The trial provided initial safety and tolerability data for Lu AF28996, with most treatment-emergent adverse events reported as mild...
- Orion Pharma ja Qilu Pharma Europe sopimukseen pembrolitsumabi-biosimilaarituotteen oikeuksista EuroopassaORION OYJ LEHDISTÖTIEDOTE 6.10.2026 KLO 9.00
- Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European marketORION CORPORATION PRESS RELEASE 6 OCTOBER 2026 at 9.00 EEST